BODIPY-Appended Pt(II) Complexes with High Toxicities and Anti-chemoresistance Performances in a Cisplatin Resistant In Vivo Model.
Chong, H
Tan, C
Fang, S
Chen, X
Tao, Q
Yuan, X
Li, J
Zhai, C
Fei, C
Yang, D
Fan, H
Shao, H
Qin, A
Wang, G
Shi, Z
Z'hang, T
Yao, H
Li, H
Wang, C
- Publisher:
- AMER CHEMICAL SOC
- Publication Type:
- Journal Article
- Citation:
- Inorg Chem, 2021, 60, (13), pp. 10047-10055
- Issue Date:
- 2021-07-05
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
acs.inorgchem.1c01471.pdf | Published version | 2.47 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Chong, H | |
dc.contributor.author | Tan, C | |
dc.contributor.author | Fang, S | |
dc.contributor.author | Chen, X | |
dc.contributor.author | Tao, Q | |
dc.contributor.author | Yuan, X | |
dc.contributor.author | Li, J | |
dc.contributor.author | Zhai, C | |
dc.contributor.author | Fei, C | |
dc.contributor.author | Yang, D | |
dc.contributor.author | Fan, H | |
dc.contributor.author | Shao, H | |
dc.contributor.author | Qin, A | |
dc.contributor.author |
Wang, G |
|
dc.contributor.author | Shi, Z | |
dc.contributor.author | Z'hang, T | |
dc.contributor.author | Yao, H | |
dc.contributor.author | Li, H | |
dc.contributor.author | Wang, C | |
dc.date.accessioned | 2022-01-17T03:55:37Z | |
dc.date.available | 2022-01-17T03:55:37Z | |
dc.date.issued | 2021-07-05 | |
dc.identifier.citation | Inorg Chem, 2021, 60, (13), pp. 10047-10055 | |
dc.identifier.issn | 0020-1669 | |
dc.identifier.issn | 1520-510X | |
dc.identifier.uri | http://hdl.handle.net/10453/153208 | |
dc.description.abstract | Two novel fluorophore (BODIPY)-bearing complexes, pyriplatin (mCBP) and pyrimidine-chelated cisplatin (dCBP), were synthesized and characterized. The additional BODIPY-pyridine/pyridimine motifs of the two Pt(II) complexes resulted in stronger interactions with DNA in comparison with those of cisplatin. mCBP and cisplatin caused relative decreases in life span and body length in a cisplatin resistant in vivo model, N2 (wild-type) Caenorhabditis elegans. In contrast, dCBP resulted in a dramatic reduction in the two physiological parameters in N2 C. elegans, indicating high toxicity and sensitivity. The resistance factors (RF) of cisplatin, mCBP, and dCBP were determined to be 2.46, 1.04, and 0.91, respectively. The increasing RF folds for mCBP and dCBP against cisplatin were 2.36 and 2.70, respectively. This suggested they were featured with improved anti-chemoresistance capabilities. It is noteworthy that dCBP showed lowest lethal concentration (LC50) values of 0.56 and 0.61 mM in cisplatin resistant and sensitive in vivo models, respectively. Upregulation of several evolutionary conservation genes that regulate cisplatin chemoresistance through cisplatin effluxing, the DNA damage response, the unfolded protein response, and detoxification (asna-1, parp-1, enpl-1, and skn-1) was observed upon exposure to cisplatin but not to mCBP and dCBP. This could explain the improved anti-chemoresistance performances of synthesized Pt(II) complexes. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | AMER CHEMICAL SOC | |
dc.relation.ispartof | Inorg Chem | |
dc.relation.isbasedon | 10.1021/acs.inorgchem.1c01471 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 0302 Inorganic Chemistry, 0306 Physical Chemistry (incl. Structural), 0399 Other Chemical Sciences | |
dc.subject.classification | Inorganic & Nuclear Chemistry | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Boron Compounds | |
dc.subject.mesh | Caenorhabditis elegans | |
dc.subject.mesh | Cell Survival | |
dc.subject.mesh | Cisplatin | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Molecular Structure | |
dc.subject.mesh | Organoplatinum Compounds | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Caenorhabditis elegans | |
dc.subject.mesh | Boron Compounds | |
dc.subject.mesh | Cisplatin | |
dc.subject.mesh | Organoplatinum Compounds | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Cell Survival | |
dc.subject.mesh | Molecular Structure | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.title | BODIPY-Appended Pt(II) Complexes with High Toxicities and Anti-chemoresistance Performances in a Cisplatin Resistant In Vivo Model. | |
dc.type | Journal Article | |
utslib.citation.volume | 60 | |
utslib.location.activity | United States | |
utslib.for | 0302 Inorganic Chemistry | |
utslib.for | 0306 Physical Chemistry (incl. Structural) | |
utslib.for | 0399 Other Chemical Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences | |
pubs.organisational-group | /University of Technology Sydney/Strength - CCET - Centre for Clean Energy Technology | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2022-01-17T03:55:35Z | |
pubs.issue | 13 | |
pubs.publication-status | Published | |
pubs.volume | 60 | |
utslib.citation.issue | 13 |
Abstract:
Two novel fluorophore (BODIPY)-bearing complexes, pyriplatin (mCBP) and pyrimidine-chelated cisplatin (dCBP), were synthesized and characterized. The additional BODIPY-pyridine/pyridimine motifs of the two Pt(II) complexes resulted in stronger interactions with DNA in comparison with those of cisplatin. mCBP and cisplatin caused relative decreases in life span and body length in a cisplatin resistant in vivo model, N2 (wild-type) Caenorhabditis elegans. In contrast, dCBP resulted in a dramatic reduction in the two physiological parameters in N2 C. elegans, indicating high toxicity and sensitivity. The resistance factors (RF) of cisplatin, mCBP, and dCBP were determined to be 2.46, 1.04, and 0.91, respectively. The increasing RF folds for mCBP and dCBP against cisplatin were 2.36 and 2.70, respectively. This suggested they were featured with improved anti-chemoresistance capabilities. It is noteworthy that dCBP showed lowest lethal concentration (LC50) values of 0.56 and 0.61 mM in cisplatin resistant and sensitive in vivo models, respectively. Upregulation of several evolutionary conservation genes that regulate cisplatin chemoresistance through cisplatin effluxing, the DNA damage response, the unfolded protein response, and detoxification (asna-1, parp-1, enpl-1, and skn-1) was observed upon exposure to cisplatin but not to mCBP and dCBP. This could explain the improved anti-chemoresistance performances of synthesized Pt(II) complexes.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph